FMT holds potential for treating various diseases beyond C. difficile infection, but its regulation by the FDA is crucial due to concerns about long-term effects and unintentional disease transfer.
Keep Reading
Add A Comment
Trending
- U.S. FDA Grants Full Approval to Pfizer’s BRAFTOVI Combination Regimen in First-Line Metastatic Colorectal Cancer (Pfizer)
- Oshi Health’s 2025 Impact Report Demonstrates Exceptional GI Outcomes and Cost Savings at Scale (PR Newswire)
- Medtronic announces CE Mark for the next generation GI Genius™ module and ColonPRO™ software (Medtronic)
- Allurion gets FDA nod for weight loss balloon (Mass Device)
- The 7 Must-Haves For The Doctor Of the 21st Century (The Medical Futurist)
- Will AI Eventually De-Skill Doctors? The Evidence Is Trickling In (Forbes)
- CRC Screening by Colonoscopy and FIT Improves Early Detection over Usual Care (Inside Precision Medicine)
- It’s Called the ‘Fitbit for Farts’—and It’s No Joke (The Wall Street Journal)
